Cytek Biosciences Inc (CTKB) — 13F Filings Explorer (Q2 2026)

CTKB ranks #3587 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CTKB is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

CTKB is a top-conviction position for Topline Capital Management, LLC — at 7.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CTKB belongs to BlackRock, Inc., but the position matters far more to Topline Capital Management, LLC, who has 7.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Israel Englander has added to its CTKB position for two straight quarters, increasing it by $17.4M to reach $41.4M today.

BlackRock has trimmed its CTKB position for two straight quarters, cutting it by $44.3M while still holding $42.4M.

CTKB is up 1.5% today, and institutions have been net buyers of $7.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CTKB reported a net loss of $48.0M over the trailing twelve months.

• Not yet profitable — net loss of $48.0M over the trailing twelve months
• Revenue grew 5.4% year over year
• Net income declined year over year, from -$27.5M to -$48.0M
• Operating cash flow was negative, using $4.7M in cash
• Current ratio of 5.04x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.35x equity — within a conventional range